Anixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

SAN JOSE, Calif. , June 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research.

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

SAN JOSE, Calif. , May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?

SAN JOSE, Calif., April 28, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022.

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

SAN JOSE, Calif. , April 6, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at The 4th International Workshop on CAR-T (iwCAR-T) 2022 on Friday, April 29, 2022.

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

SAN JOSE, Calif. , March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer.

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

SAN JOSE, Calif. , March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the Company will present at the 2022 Virtual Growth Conference, hosted by M-Vest, a division of Maxim Group LLC, on March 28 th – 30th from 9:00 am – 5:00 pm EDT.

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines.

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus.

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

SAN JOSE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C.

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19.

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

SAN JOSE, Calif. and CLEVELAND , Oct. 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated for preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

SAN JOSE, Calif., Oct. 6, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the China National Intellectual Property Administration (CNIPA) has issued a Notification of Grant of Patent Right on Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T technology," which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T technology," which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021.

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C.

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D.

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

The FDA has signed off Anixa Biosciences Inc's (NASDAQ: ANIX) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center. Anixa Biosciences has an exclusive worldwide license to the technology.

Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer

SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center (Moffitt).

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

Anixa Biosciences Inc (NASDAQ: ANIX) has announced that a genomic variant analysis indicates that its potential compounds may be more effective against the Delta variant than the original wild-type SARS-CoV-2.  Anixa's program, in collaboration with European partner MolGenie, focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the virus.

Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta Variant

SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Director, Dr. Arnold Baskies has been appointed to the World Health Organization's (WHO) Global Breast Cancer Initiative.

News for Anixa Biosciences Inc Stock (ANIX)